Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
13.52
+0.03 (0.22%)
At close: Jul 17, 2026, 4:00 PM EDT
13.50
-0.02 (-0.15%)
After-hours: Jul 17, 2026, 7:00 PM EDT
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$616,300
Profits / Employee
$24,600
Market Cap
3.55B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10,000 | 0 | - |
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Amgen | 31,500 |
| Grifols | 25,247 |
| Gilead Sciences | 17,000 |
OGN News
- 2 days ago - Organon & Co. Proxy statement: Proxy filing - Filings
- 3 days ago - Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing - Business Wire
- 26 days ago - Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA - Business Wire
- 27 days ago - Organon completes agreement to license MIUDELLA hormone-free IUD - TheFly
- 27 days ago - Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device - Business Wire
- 4 weeks ago - Organon and Samsung Bioepis expand commercialization agreement for Pyzchiva - TheFly
- 4 weeks ago - Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada - Business Wire
- 4 weeks ago - Organon & Co. Proxy statement: Proxy filing - Filings